TRANSTHERA-B (02617.HK), a Hong Kong-listed pre-revenue biotech company, announced a new share placement after market close on April 14, 2026. The company plans to issue 5.085 million new H shares at HK$57.03 per share to no fewer than six professional and institutional investors, aiming to raise approximately HK$290 million in total, with net proceeds of about HK$282 million. This marks the company's second financing round since its listing in June 2025, bringing cumulative fundraising to HK$630 million when combined with its IPO proceeds.
The placement price of HK$57.03 represents an 18% discount to the closing price of HK$69.55 on April 14, 2026, and a 19.2% discount to the average closing price over the preceding five trading days. This discount level is notably high compared to recent placement activities in the market.
However, the announcement failed to provide positive support for the stock price. By April 30, 2026, TRANSTHERA-B's shares closed at HK$51.60, representing a 9.5% discount to the placement price and a cumulative decline of over 25% since before the announcement. Investors participating in the placement are already facing paper losses.
The company's share price had previously surged to a historical high of HK$679.5 in September 2025 during the inclusion window for the Stock Connect program, but subsequently retreated rapidly. The current price represents a significant decline from that peak, indicating that market enthusiasm has substantially diminished.
TRANSTHERA-B's fundraising frequency is unusual even among pre-revenue biotech companies. The company raised HK$200 million through its IPO in June 2025, followed by a HK$190 million placement in January 2026 at HK$92.85 per share. With this third round, total fundraising has reached HK$680 million.
Notably, according to the placement announcement dated April 14, 2026, the net proceeds of approximately HK$190 million from the January 2026 placement remained entirely unused as of February 28, 2026. The management's decision to initiate another placement at a substantial discount while previous funds remain idle has raised market concerns about the rationality of the company's capital planning.
TRANSTHERA-B has yet to commercialize any products. According to annual results disclosed on March 31, 2026, the company reported a net loss of RMB 296 million for 2025, widening from RMB 275 million in 2024. Cumulative losses over three years have now exceeded RMB 900 million.
As of December 2025, the company held cash and cash equivalents of RMB 415 million. At the current annual loss rate of nearly RMB 300 million, existing cash reserves can only sustain operations for approximately eighteen months. The company plans to allocate approximately 57% (HK$161 million) of the placement proceeds to clinical development of its core product tinengotinib, with about 33% (HK$93.11 million) designated for commercialization preparations.
The company has achieved some developmental milestones. Its new drug application for tinengotinib for treating FGFR inhibitor-resistant cholangiocarcinoma was accepted by China's Center for Drug Evaluation in December 2025 and granted priority review status. Approval is expected in 2026, which would make it the company's first commercial product.
However, market access, physician education, and医保 negotiations present significant challenges for a research-focused company with no prior commercialization experience. The allocation of approximately 33% of placement proceeds to build a commercial team and marketing activities carries high uncertainty regarding its ability to generate sustainable revenue in the short term. Additionally, tinengotinib continues to advance in global multicenter Phase III trials and multiple Phase II trials for other indications, indicating that research and development expenditures will continue to consume substantial cash resources.
Comments